EP2320844A1 - Wundpflegeartikel, aufweisend einen anteil an modifizierten naturfasern oder an kunstfasern - Google Patents
Wundpflegeartikel, aufweisend einen anteil an modifizierten naturfasern oder an kunstfasernInfo
- Publication number
- EP2320844A1 EP2320844A1 EP09782710A EP09782710A EP2320844A1 EP 2320844 A1 EP2320844 A1 EP 2320844A1 EP 09782710 A EP09782710 A EP 09782710A EP 09782710 A EP09782710 A EP 09782710A EP 2320844 A1 EP2320844 A1 EP 2320844A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- wound
- fibers
- care article
- wound care
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000835 fiber Substances 0.000 title claims abstract description 206
- 229920002994 synthetic fiber Polymers 0.000 title claims abstract description 9
- 239000012209 synthetic fiber Substances 0.000 title claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 208000027418 Wounds and injury Diseases 0.000 claims description 339
- 206010052428 Wound Diseases 0.000 claims description 338
- 229920000247 superabsorbent polymer Polymers 0.000 claims description 59
- 239000000463 material Substances 0.000 claims description 58
- 239000004583 superabsorbent polymers (SAPs) Substances 0.000 claims description 58
- 210000000416 exudates and transudate Anatomy 0.000 claims description 51
- 239000002250 absorbent Substances 0.000 claims description 34
- 230000002745 absorbent Effects 0.000 claims description 33
- 229920002678 cellulose Polymers 0.000 claims description 22
- 239000001913 cellulose Substances 0.000 claims description 22
- 235000010980 cellulose Nutrition 0.000 claims description 22
- 238000010521 absorption reaction Methods 0.000 claims description 21
- 229920000742 Cotton Polymers 0.000 claims description 15
- 239000006260 foam Substances 0.000 claims description 14
- 230000001684 chronic effect Effects 0.000 claims description 13
- 230000000740 bleeding effect Effects 0.000 claims description 11
- 238000007906 compression Methods 0.000 claims description 11
- 230000006835 compression Effects 0.000 claims description 11
- 229920000615 alginic acid Polymers 0.000 claims description 10
- 235000010443 alginic acid Nutrition 0.000 claims description 10
- 238000002803 maceration Methods 0.000 claims description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 229920002488 Hemicellulose Polymers 0.000 claims description 3
- 239000005445 natural material Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 238000001311 chemical methods and process Methods 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000004744 fabric Substances 0.000 description 39
- 239000007788 liquid Substances 0.000 description 28
- 239000013543 active substance Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 20
- -1 polypropylene Polymers 0.000 description 18
- 230000008569 process Effects 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 230000029663 wound healing Effects 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 239000000853 adhesive Substances 0.000 description 13
- 229920000297 Rayon Polymers 0.000 description 12
- 230000001070 adhesive effect Effects 0.000 description 12
- 208000032843 Hemorrhage Diseases 0.000 description 11
- 239000004365 Protease Substances 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- 108091005804 Peptidases Proteins 0.000 description 10
- 208000034158 bleeding Diseases 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 229920001410 Microfiber Polymers 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 239000003658 microfiber Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 239000004743 Polypropylene Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000004745 nonwoven fabric Substances 0.000 description 7
- 230000000050 nutritive effect Effects 0.000 description 7
- 229920001155 polypropylene Polymers 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 108010006035 Metalloproteases Proteins 0.000 description 6
- 102000005741 Metalloproteases Human genes 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 239000004753 textile Substances 0.000 description 6
- 229920003043 Cellulose fiber Polymers 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 241000243142 Porifera Species 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000003466 welding Methods 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229920000433 Lyocell Polymers 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 230000000249 desinfective effect Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 230000008092 positive effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002964 rayon Substances 0.000 description 4
- 239000004627 regenerated cellulose Substances 0.000 description 4
- 230000008093 supporting effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000000472 traumatic effect Effects 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000005517 mercerization Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000058 polyacrylate Polymers 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 101000898643 Candida albicans Vacuolar aspartic protease Proteins 0.000 description 2
- 101000898783 Candida tropicalis Candidapepsin Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 101000898784 Cryphonectria parasitica Endothiapepsin Proteins 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 229920001131 Pulp (paper) Polymers 0.000 description 2
- 101000933133 Rhizopus niveus Rhizopuspepsin-1 Proteins 0.000 description 2
- 101000910082 Rhizopus niveus Rhizopuspepsin-2 Proteins 0.000 description 2
- 101000910079 Rhizopus niveus Rhizopuspepsin-3 Proteins 0.000 description 2
- 101000910086 Rhizopus niveus Rhizopuspepsin-4 Proteins 0.000 description 2
- 101000910088 Rhizopus niveus Rhizopuspepsin-5 Proteins 0.000 description 2
- 101000898773 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Saccharopepsin Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 206010053692 Wound complication Diseases 0.000 description 2
- 238000004026 adhesive bonding Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000003490 calendering Methods 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000000025 haemostatic effect Effects 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000005871 repellent Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- 239000010457 zeolite Substances 0.000 description 2
- PQUXFUBNSYCQAL-UHFFFAOYSA-N 1-(2,3-difluorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(F)=C1F PQUXFUBNSYCQAL-UHFFFAOYSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 1
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 1
- 206010060964 Arterial haemorrhage Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000243143 Demospongiae Species 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010023125 Jarisch-Herxheimer reaction Diseases 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 108010014603 Leukocidins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910000861 Mg alloy Inorganic materials 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 229920002323 Silicone foam Polymers 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 229920001872 Spider silk Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 230000007921 bacterial pathogenicity Effects 0.000 description 1
- 230000002368 bacteriocinic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011111 cardboard Substances 0.000 description 1
- 238000009960 carding Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 238000007730 finishing process Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 230000009442 healing mechanism Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003282 necrolytic effect Effects 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000001066 phage therapy Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 239000013514 silicone foam Substances 0.000 description 1
- 229940083025 silver preparation Drugs 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229940047670 sodium acrylate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01034—Non-adhesive bandages or dressings characterised by a property
- A61F13/01042—Absorbency
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
- A61F13/01017—Non-adhesive bandages or dressings characterised by the material synthetic, e.g. polymer based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0206—Adhesive bandages or dressings with fluid retention members with absorbent fibrous layers, e.g. woven or non-woven absorbent pads or island dressings
- A61F13/0209—Adhesive bandages or dressings with fluid retention members with absorbent fibrous layers, e.g. woven or non-woven absorbent pads or island dressings comprising superabsorbent material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/022—Adhesive bandages or dressings with fluid retention members having more than one layer with different fluid retention characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
- A61F13/53—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium
- A61F13/534—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad
- A61F13/537—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators characterised by the absorbing medium having an inhomogeneous composition through the thickness of the pad characterised by a layer facilitating or inhibiting flow in one direction or plane, e.g. a wicking layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00157—Wound bandages for burns or skin transplants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00519—Plasters use for treating burn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00536—Plasters use for draining or irrigating wounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00553—Plasters form or structure with detachable parts
- A61F2013/00557—Plasters form or structure with detachable parts detachable absorbent pad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00655—Plasters adhesive
- A61F2013/00659—Plasters adhesive polymeric base
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00655—Plasters adhesive
- A61F2013/00697—Plasters adhesive elastomer-, e.g. rubber- based
- A61F2013/00702—Plasters adhesive elastomer-, e.g. rubber- based silicon-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00731—Plasters means for wound humidity control with absorbing pads
- A61F2013/0074—Plasters means for wound humidity control with absorbing pads containing foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00748—Plasters means for wound humidity control with hydrocolloids or superabsorbers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00897—Plasters package for individual plaster
Definitions
- Wound care article comprising a proportion of modified natural fibers or on
- the invention relates to a wound care article comprising a proportion of modified natural fibers or of synthetic fibers which have a high dewatering capacity.
- wound care articles in particular wound dressings, consist for the most part of fibers of natural origin, in particular cellulose and cellulose derivatives, since these are capable of absorbing fluids, in particular blood and exudate.
- wound care articles additionally contain synthetic polymers or fibers which impart special properties to the articles. This can e.g. a one-sided wrapping of a water-impermeable film acting as a laundry protector, or a wound-facing film of a non-wound-adherent polymer.
- the wound dressing also receives special properties, such as increasing the absorption capacity of wound fluids.
- Such conventional wound dressings are known, for example, from DE 10059439, DE20207356, DE102007036758, DE102007036757, DE 102007049430, DE 102007049429 and DE102007 049428 by the applicant of the present invention, the disclosure content of which is to be regarded as added to the present application.
- Natural fibers have a number of disadvantages. Natural fibers are wettable and usually absorb moisture (water absorption capacity), but they do not last forever. This behavior may, for example, lead to wound marginal maceration (softening and inflammation of the surrounding skin through prolonged contact with a fluid) and also accelerate the growth of bacteria as they find the required moist (and often warm) microclimate in appropriate wound care articles. Likewise, when wetting, natural fibers often lose their structural integrity and thus their cushioning and possibly heat-insulating properties.
- the object of the present invention is therefore to provide a wound care article which does not have the mentioned disadvantages of the products of the prior art.
- This object is achieved with a wound care article according to the present main claim; the dependent claims indicate preferred embodiments.
- ranges of values which are limited by numerical values are always to be understood as including the stated numerical values.
- a wound care article which has a proportion of modified natural fibers or synthetic fibers, which have a high dewatering capacity.
- the modified natural fibers used for the wound care article are preferably chemically or physically modified natural fibers, such as cotton.
- the fibers are usually made of cellulose (cellulose).
- Cellulose is an unbranched polymer of 1-4-ß-glycosidically linked glucose molecules with a chain length between one hundred and ten thousand monomers.
- the proportion of fibers used may also be a mixture of synthetic and natural fibers.
- extracted chemical cellulose is suitable, which can be prepared by digestion of wood via the acid sulfite process, since this has a low content of hemicellulose and resin and thus an excellent whiteness due to its very low yellow content , whereby their use in the hygiene sector is preferred.
- An example of a natural fiber modified via a sulfite process is, for example, PLACETATE-F from Rayonier Performance Fibers, which has an extremely high degree of whiteness.
- modified natural fibers for use in the wound care article according to the invention are HPZ, HPZ-III and HPZ-XS from woodpulp, as well as the bleached chemical cellulose known under the name SULFATATE-HJ modified natural fibers from PLACETATE-F company.
- the fibers may also be microfibers if their
- Wt .-% of the wound care article corresponds, or that the proportion of fibers in a range of 0.1 to 99 wt .-% of the total content of the wound care article is.
- the proportion of fibers is in a range of 5-20% by weight of the total content of the wound care article, whereby such a proportion of fibers for a wound care article is suitable for the treatment of aqueous wounds.
- the proportion of the fibers according to the invention is in a range of 90-100% by weight of the total portion of the wound care article, whereby such a proportion of fibers for a wound care article is suitable for the treatment of dry wounds with little exudation.
- the proportion of fibers can also be understood as meaning that the fiber is present in a homogeneous, all-fiber layer at a weight proportion of 100%, or this layer is proportionally mixed with other fibers / substances, in which case the proportion of the fibers according to the invention is less than 100% by weight.
- a fiber content of 100 wt .-% is particularly suitable for a wound care article according to the invention, which can be added under one of the wound dressings known in the market.
- a wound care article according to the invention which has a recess in the area of the wound, and in its dimensions corresponds to the dimensions of the wound dressing to be applied so that the wound care article according to the invention lies as a frame below the wound dressing, effectively keeping the wound edges dry and thus providing protection against wound edge maceration.
- the size of the wound dressing allows it to retain its unrestricted contact with the wound.
- Fibers with increased drainability are known from the hygiene sector, household and partly also from the textile sector.
- a use in wound care articles has not yet been proposed, since it was to be assumed at the time of this application that the natural fibers modified mostly by chemical processes, such as the mercerization or the sulfite process, exhibit toxicity to the cells and in particular have a toxic effect on contact with a wound would.
- the modified natural fibers have some excellent physical properties as compared with conventional natural fibers, making them suitable for use in wound care articles.
- the modified natural fibers are characterized by a good moisture absorption with simultaneous ability to dissipate moisture quickly, with adjacent layers are dried out, kept dry or back-dried.
- the toxicity test also showed that there is no increased toxicity of the modified natural fibers to cells.
- the fibers have said properties both in the wetted and in the unwetted state. It is the essence of the present invention that it is proposed for the first time to make the outstanding physical properties of chemically modified natural fibers usable for wound care.
- modified natural fibers such as mercerized fibers
- these fibers as well as other chemically modified fibers (for example also known as "curled fibers" or the cellulose which has been converted by the sulfite process from cellulose, can also be used for the treatment of wounds, due in part to the fact that experts in the field of wound care have so far always been concerned with wound care the category of swelling and / or moisture-absorbing materials, such as cellulose, carboxymethyl cellulose or alginates.
- superabsorbent polymers an idea to which the assignee of the present invention has, moreover, done pioneering work.
- modified natural fiber with high drainage capacity in wound care now proposed for the first time violates this category of thinking, and only overcoming this thinking - as the applicant of the present invention has done - leaves the specific advantages of using the modified natural fiber with high dewatering capacity become recognizable in the wound care.
- modified natural fibers have a low moisture absorption reduces e.g. the aforementioned wound edge maceration, since the wound edges in contact with the sections have low moisture.
- the moisture wicking properties are particularly advantageous when the modified fibers are placed in combination with a fluid absorbent portion in a wound care article, preferably such that the fibers directly contact the wound while absorbing in a second layer the liquids Section is arranged.
- exudate exiting the fiber section (which acts like a kind of transit layer, similar to sports underwear) passes quickly and is transported into the absorbent section; the wound-contacting portion containing fibers thus remains dry.
- a wound care article as opposed to wound care articles, can be treated with e.g. moisture-absorbing cellulose fibers does not collapse or collapse when in contact with liquid, and thus preserves the structural integrity of the wound care article, or recovers it through rapid drying, which in particular brings about cushioning and heat-insulating properties.
- the rapid wicking prevents lateral diffusion of moisture within the wound care article, which could otherwise result in maceration of the healthy skin surrounding the wound.
- a vertical alignment of the fibers to the absorbent body is no longer necessary, since the absorbent body takes over the targeted guidance of the liquid.
- the rapid passage of moisture prevents the formation of a moist environment promoting the growth of microorganisms, in particular bacteria, within the wound care article.
- the wound care article according to the invention is also suitable for breaking up biofilms on the wound.
- biofilms consist of a thin layer of mucus (film) in which microorganisms (eg bacteria, algae, fungi, protozoa) are embedded.
- microorganisms eg bacteria, algae, fungi, protozoa
- Biofilms are formed when microorganisms settle at interfaces. They form predominantly in aqueous systems, either on the water surface or at an interface to a solid phase, e.g. of the skin.
- biofilms play a major role in chronic and acutely infected wounds, as they reduce the metabolic exchange with the environment, make it difficult to cleanse wounds and jeopardize wound healing through their proteolytic properties and excreted endotoxins.
- biofilms in the wound usually can not be treated with antibiotics or disinfecting agents.
- said agents kill the bacteria of the uppermost layer of the biofilm, while the underlying layers remain unimpaired, the latter possibly being unaffected. still benefit from the remnants of killed bacteria.
- an absorbent body may be provided which is capable of absorbing the released bacteria of the biofilm or its released components (especially endotoxins). This will be discussed later.
- the treated patient perceives the desiccation or drying of the layers applied to the modified fibers, which may also be directly skin layers of the patient, as extremely pleasant, since, as already described above, maceration of the intact skin layers is effectively prevented for the first time ,
- the low tendency to adhesion of modified fibers with increased dewatering capacity or wound care articles made therefrom at the wound surface leads to a reduction of the pain-intensive wound impairment during dressing changes and thus enables almost atraumatic dressing changes.
- the modified fibers are present in the wound care article according to the invention in the form of a wadding, a fleece, a pile, a terry cloth, a terry velor, a fabric or a knitted fabric.
- Said nonwovens can be present, for example, in the form of a nonwoven swirl fleece.
- a nonwoven also consist of a simple carded fiber wadding. It is preferably provided that the fibers form a nonwoven with a density between 5.0 and 50.0 g / cm 2 . Most preferably, the fibers form a nonwoven having a density between 6.0 and 20.0 g / cm 2 .
- Said piles consist of a microfine fiber material which has been flocked onto a carrier material, but they can likewise consist of a matrix fabric or knitted fabrics into which pile threads are incorporated.
- the modified fibers are formed as a monofilament in a composite with absorbent threads, wherein the absorbent threads and the monofilaments in are essentially the same length and anchored in a textile base fabric, knitted fabric, knitted or a rigid back plate by welding or gluing.
- the proportion of monofilaments may be 5 to 50%, usually between 10 and 40%, of the total number of absorbent threads and monofins.
- the monofilaments are incorporated together with the absorbent threads as a pole in a base fabric. They should be anchored in the base fabric by welding, for which z. B.
- the monofilaments are firmly held. They can not push themselves out backwards, despite the considerable force with which they support themselves in the tissue due to their rigidity.
- the welding also surrounds the monofilaments without gaps over their entire circumference, so that bending moments are transferred completely into the fabric and the monofilaments can not bend off due to angling relative to the base fabric.
- the backing fabric can be made stiff enough to hold the bending forces.
- modified natural fibers in hydrophobic and hydrophilic design are conceivable.
- hydrophilic fibers like hydrophilic fibers, do not absorb liquid on water (i.e., do not swell), they are wettable and, therefore, can buffer liquid in a three-dimensional fiber structure. However, unlike swelling fibers, they quickly release the liquid, e.g. if they have an actively absorbing wound dressing, such as the Sorbion Sachet is highlighted.
- the fibers have moisture-conducting properties and, in particular, prevent the formation of a microclimate that promotes bacterial growth.
- hydrophilic and hydrophobic fibers can be provided here.
- dedicated drainage areas can be formed in the wound care article, which have hydrophilic microfibers, while surrounding areas having hydrophobic areas convey exudate to said drainage areas.
- the modified natural fibers are twisted or twisted into yarns or multifilaments before they are processed, for example, into a pile or a fabric.
- the wound care article is a wound dressing.
- said wound dressing may e.g. be formed flat and have a round, elliptical, rectangular or polygonal shape.
- the wound care article may also be a wound-care cloth, a swab, a tampon, a wound tamponade or the like. These may have absorbent and non-absorbent properties.
- the wound care article according to the invention with proportion of chemically and / or physically modified fibers can be cut and present in the form of a tubular dressing.
- the wound care article has at least one body which absorbs wound exudates and a shell which is arranged at least in sections around this body.
- the wound exudate absorbing body preferably comprises a material which is selected from the group comprising a mat, in particular from an airlaid having superabsorbent polymers, and / or a loose filling of superabsorbent polymers.
- Said airlaid mat may preferably have a substantially flat material portion of absorbent material, the z. B. consists of an absorbent fleece with superabsorbent polymers distributed therein.
- This wound exudate absorbing body may correspond to the absorbent pad contained in a wound dressing of the assignee of the present invention, as disclosed, for example, in WO03094813, WO2007051599 and WO0152780, and sold under the trade name "sorbion sachet.”
- WO03094813 WO2007051599 and WO0152780
- sorbion sachet sold under the trade name "sorbion sachet."
- the wound-absorbent body can likewise form a core which-optionally flake-like-has fibers or yarns of superabsorbent polymers and superabsorbent polymers in granular form, the granules being adhesively bonded or welded to the fibers or yarns at several heights , and the granules are distributed over more than 50% of the total height of at least a portion of the core, wherein there are mixed areas of granules and fibers.
- the proportion by weight of the superabsorbent polymers may preferably be in the range between 10 and 25% by weight for use as a wound compress.
- the wound exudate absorbing body may also include at least one flat layer comprising fibers or yarns of superabsorbent polymers to which superabsorbent polymers in granular form are adhered.
- the body may have repetitive patterns or grains such as e.g. a check pattern, a stamping pattern, a company logo or the like.
- this core may be disposed a shell which is overlapped in areas, and e.g. an adhesive seam is covered or part of the same.
- a portion of a hydrophobic and / or water-repellent or water-impermeable material may be provided within the envelope, which acts as a soaking or laundry protection.
- said shell has the modified natural fibers, which are preferably prepared in the form of a fabric, a knitted fabric, a nonwovens or a nonwoven.
- a section comprising the modified Natural fibers is arranged within the envelope.
- the inside of the sheath fiber section then serves well for the re-drying of the shell.
- said section is preferably arranged on the wound-facing side of the wound care article and can consist, for example, of a three-dimensional nonwoven web.
- such a section may e.g. also consist of a three-dimensional knitted fabric, woven or knitted fabric.
- spacer knitted fabric has highly cushioning properties and, on the other hand, has a high respiratory activity and moisture-wicking properties, so that it is guaranteed that the wound will remain open even in the event of heat and / or perspiration to a certain degree, not exceeding the wound-healing moist environment, dries.
- An embodiment of such woven, knitted or crocheted fabrics or even tufted fabrics made of chemically and / or physically modified fibers may have a dissimilarity or blending of two different fabrics, one of which is hydrophobic and the other is hydrophilic.
- the modified natural fibers consist of biodegradable materials which, as known from surgical suture materials, can be coated with a biodegradable magnesium alloy, which supports the biocompatibility and the body's own healing and defense mechanisms in wound healing.
- the shell has a pattern of different, modified natural fibers containing materials.
- the sheath may have a stripe or check pattern, with individual sections each dissipating more moisture than other sections.
- the wound care article also has superabsorbent polymers.
- Superabsorbent polymers are plastics that are able to absorb many times their own weight - up to 1000 times - in liquids. Chemically, this is a copolymer of acrylic acid (propionic acid, C3H4O2) and sodium acrylate (sodium salt of acrylic acid, NaCsHsO 2 ), wherein the ratio of the two monomers may vary.
- a so-called core crosslinker core cross-linker, CXL
- CXL core cross-linker
- CXL core cross-linker
- exudate refers to a wound fluid derived from the blood plasma via the inflammatory processes of wound edema. Just as the blood is responsible for the transport of nutrients and other messengers, and thus for the supply of various parts of the body, the exudate serves in a similar way the supply of the wound bed and the healing processes occurring therein. To cope with this multitude of functions, it contains a wide range of components, resulting in a specific weight that is slightly above that of water.
- exudate coordinates the various processes of wound healing both temporally and spatially through its high content of growth factors and cytokines. These are mainly through Platelets, keratinocytes, macrophages and fibroblasts formed. They influence the motility, migration and proliferation of the various cells involved in wound healing. Thus, the infiltration of cells into the wound base is promoted as well as the supply of the newly formed granulation tissue by angiogenesis.
- the wound cleansing is also supported by the exudate. It contains several serine, cysteine and aspartate proteases as well as matrix metalloproteases, which are tightly regulated in their activity and degrade both existing and newly formed collagen in the wound.
- Components of the physiological exudate are in particular salts, glucose, cytokines and growth factors, plasma proteins, proteases (in particular matrix metalloproteases), granulocytes and macrophages.
- the normally healing-promoting exudate loses its positive effect in chronic wounds.
- the content of inflammatory cytokines and proteases is significantly increased in pathological exudate.
- the content of growth factors is reduced.
- a particularly serious difference arises with regard to the activity of the previously mentioned matrix metalloproteases.
- These enzymes are normally formed as an inactive pre-enzyme and are regulated in their activation by appropriate inhibitors (tissue inhibitors of metalloproteases, TIMPs), which at the same time have a positive effect on cell growth.
- the said component comprising SAP is of particular importance.
- the intended share of SAP serves to absorb the fragments and remnants of the biofilm.
- the destruction of the biofilm may also release endotoxins and bacterial pathogenicity factors (especially bacterial hemolysin and leucocidin) that can cause inflammation, allergies, shock (especially anaphylactic shock and / or toxic shock syndrome) and fever in the patient (Herxheimer reaction ). Said endotoxins and pathogenicity factors are taken up by the proportion of SAP, so that the said consequences can be avoided.
- the superabsorbent polymers are polymers in powder or granular form.
- Superabsorbent polymers in this dosage form have a variety of advantages, e.g. from WOO 152780 and WO03094813 of the applicant of the present invention.
- the superabsorbent polymers are polymers in fiber, yarn, cotton, nonwoven or fabric form.
- the proposed use of superabsorbent polymers in fiber or yarn form has a number of advantages over particulate superabsorbent polymers:
- said fibers or yarns have a wicking effect.
- the liquid streams can direct.
- a wound edge maceration can be prevented.
- Unlike particulate superabsorbent polymers they can be made into nonwovens, fabrics or the like. In this way, for example, the casing of a wound dressing can be made of these fibers or yarns, and the superabsorbent properties can be brought much closer to the wound base.
- Said fibers or yarns can be processed into a structure, without the need - as is the case with particulate superabsorbent polymers - an adhesive or a welding process must be used. This has significant advantages in terms of product purity as well as pharmacology and potential allergenicity.
- Due to the lack of formation of dusts may possibly be dispensed with the use of a separate shell.
- Said yarns or fibers in prior art airlaids containing particulate superabsorbent polymers, can replace the carrier fibers of the airlaid, thus reducing the proportion of superabsorbent materials in a sanitary or personal care article, especially a wound care article, and hence the total absorbent capacity - increase.
- the fibers or yarns may be directional or non-directional (Wirr-Warr), in multiple layers or otherwise.
- Superabsorbent fibers of polyacrylates are e.g. offered by the company Technical Absorbents under the trade name "Oasis Super Absorbent Fiber” and, like all superabsorbent polyacrylates, have a very high absorption capacity for liquids such as nonwoven, airlaid, fabric, airlaid and Such fibers are known, for example, from DE 69807337
- the said fibers of superabsorbent material are, however, usually very brittle, since the polyacrylate material used has a high brittleness. For this reason, the fibers can not exceed a certain length and therefore can not be easily processed into a yarn.
- WO 106047 describes yarns comprising superabsorbent polymers. These yarns are based on a special manufacturing process in which the abovementioned superabsorbent fibers are mixed with supporting fibers of a stronger material and then spun into a yarn.
- said supporting fibers are fibers of polyester, polypropylene, nylon, cotton, viscose or similar material.
- the yarn thus produced can then be made into a fabric, Scrim, knit and / or knitted fabric are processed.
- the fibers can also be processed with elastic fibers, such as spandex.
- the superabsorbent polymers present in fiber form are present at least partially in the form of a wadding, a fleece, an airlaid and / or a nonwoven.
- fibers are used with average lengths of 5 - 50 mm.
- the preparation is carried out by known methods, e.g. carding or airlaid.
- the superabsorbent fibers may be the sole constituent of the respective material.
- the hygiene or care article also has a proportion of supporting fibers that ensure the integrity of the wound dressing even when wet, said fibers are selected from the group containing
- cellulose fibers a) cellulose fibers, b) viscose fibers, c) alginate fibers, and / or d) polyester, polyolefm, polyurethane, polyvinyl alcohol or polymaid fibers, or mixtures or copolymers thereof.
- a fabric in which, for example, the warp threads are made of superabsorbent yarns, while the weft threads consist of other yarns containing, for example, supporting fibers according to the above list.
- a fabric has directional hydroactive properties, ie it takes up liquid in one direction and passes it on.
- the fibers may preferably be present at least partially in the form of a nonwoven, a woven fabric, a knitted fabric, an airlaid and / or a nonwoven.
- modified natural fibers are present at least in sections in a composite with other materials, in particular fibers.
- This may be e.g. contains cotton wool, fluff pulp, medical cotton wool, viscose staple, pulp fluff, regenerated cellulose, snippets, rayon, viscose, modal and / or tencel.
- snippets is to be understood in the following as meaning particles obtained from rupture, punching or cutting of a cellulosic material
- Such snippets may be made, for example, from an airlaid which optionally contains superabsorbent polymers and in the latter form in the applicant's WO03094813 Present invention is described.
- cell wool is to be understood in the following text consisting of a pulp, cotton wool-like material.
- pulp flakes is to be understood below as fluffy pulp particles, as used in the diaper technology.
- Regenerated cellulose generally refers to fibers such as viscose, lyocell, modal, rayon or copper silk.
- “Fluff pulp” is a standardized product made of wood, which is produced, for example, from cellulosic material supplied in sheets or webs, so-called wood pulp cardboards, which are usually comminuted in hammer mills or spiked and frayed with scratching apparatus before use a cotton-like product of cellulose fibers has arisen.
- the resulting material is preferably bleached without chlorine.
- Such a mixture can have a wicking effect, thus improving the moisture-conducting properties of the wound care article according to the invention.
- CMC carboxymethylcellulose
- a blend of CMC or superabsorbent polymer fibers and the modified natural fibers partially transforms into a gel upon moisture uptake while preserving its structural integrity.
- the mixing ratios between the modified natural fibers and other fibers, or between hydrophilic and hydrophobic fiber types can be used to precisely control the moisture-conducting or moisture-binding properties of the wound care article according to the invention.
- the mixing ratios between the modified natural fibers and other fibers, or between hydrophilic and hydrophobic fiber types can be used to precisely control the moisture-conducting or moisture-binding properties of the wound care article according to the invention.
- the material of the shell has at least one hydrophobic and / or non-bonded with the wound portion.
- Such a material effectively prevents the wound dressing from sticking to the wound, thereby reducing trauma to dressing changes.
- These are particularly preferably mercerized cotton, but there are also regenerated cellulose such as viscose, lyocell, modal, rayon or copper silk, polyamide (nylon), polyethylene, polypropylene, PTFE (Teflon), siliconized fibers or similar materials conceivable. In particular, it may also be straight, wavy, crimped and / or mercerized fibers, in particular fibers of natural materials are preferred.
- the shell may comprise a layer containing superabsorbent polymers in fibrous form.
- a shell is eg in the DE 102007036758 the applicant of the present invention is described, the contents of which are fully referenced here.
- the material particularly preferably has a three-dimensional pore structure, as described, for example, in US Pat. is described in the WO2007118652 the assignee of the present invention, the contents of which are fully referenced here.
- Said shell may preferably consist of a nonwoven polypropylene or polyethylene having a weight per unit area of> 10 to ⁇ 100 g / m 2 , preferably of> 20 to ⁇ 40 g / m 2 .
- a portion of a hydrophobic and / or water-repellent or water-impermeable material may be provided within the shell, which acts as Naturalnässungs- or laundry protection.
- the superabsorbent polymers used are immobilized within the wound dressing. This is important to prevent trickling of the polymers from the wound dressing into the wound.
- Said immobilization can be done in different ways.
- the superabsorbent polymers are glued to fibers of the wound dressing, eg with a hotmelt adhesive; b) the superabsorbent polymers are compressed with fibers of the wound dressing; c) the superabsorbent polymers are firmly embedded in a three-dimensional fiber matrix; d) the section of the wound dressing containing the superabsorbent polymers is surrounded by a shell which, for example by selecting a suitable pore size or by omitting pores, is impermeable to the polymers (this may be the outer cover of the wound dressing, but also um an inner shell disposed within the outer shell); e) the superabsorbent polymers are in the form of fibers, wherein the fibers are present in the form of a fiber composite and possibly even form a bond with the cellulose fibers of the wound dressing.
- the material of the shell on no intentionally introduced pores are pores in the material possibly given by the mesh size of the fabric or the fiber spacing of the web.
- the material of the shell intentionally introduced pores the pore size depends on the size of the superabsorbent particles used, and may assume values of ⁇ 50 to ⁇ 5000 microns, preferably ⁇ 100 to ⁇ 3000 microns.
- the wound dressing further comprises
- a) a section comprising flexible foam b) a section end modified C ellulo se, in particular Carboxymethylcellulose, and / or c) a section comprising alginates, and / or d) a section comprising a nonwoven and / or an airlaid mat, or Snippets of the same.
- airlaid refers to a special nonwoven fabric made of pulp and polyolefin fibers, in which possibly superabsorbent polymers are embedded. This may be, for example. to the airlaid mat contained in the product "Sorbion Sachet", which is described in WO03094813 the assignee of the present invention act.
- the airlaid may be over or underlaid with a proportion of pulp, e.g. a proportion of cotton wool, fluff pulp, medical cotton wool, viscose staple, pulp fluff, regenerated cellulose, snippets, rayon, viscose, modal and / or tencel, said portion containing in addition to the airlaid or exclusively a proportion of superabsorbent polymers.
- a proportion of pulp e.g. a proportion of cotton wool, fluff pulp, medical cotton wool, viscose staple, pulp fluff, regenerated cellulose, snippets, rayon, viscose, modal and / or tencel
- nonwoven refers to a textile fabric of individual fibers which, unlike woven fabrics, knitted fabrics and knitted fabrics, is not made of yarns Nonwovens tend to retain their structural integrity as a result of the adhesion of the individual fibers and are referred to as “nonwovens”. and eg made by swaging the fibers
- said foam may be a material selected from the group consisting of thermoplastic flexible foams, such as polyurethane, polyamide or Polyether foam, silicone foam and cellulose foam or natural sponge is. Said foam may preferably have dimensionally stable properties.
- Natural sponges for example, the class of Hornkieselsch tediousmme (Demospongiae), similar to technical foams have an absorbency for liquids. In addition, they have growth-inhibiting properties against microorganisms to protect against the settling of sessile organisms. These properties may also be useful in the context of wound care to prevent bacterial growth in the wound dressing and / or wound. Likewise, these sponges have growth-inhibiting properties against fungi and unicellulars. In addition, such sponges are able to absorb liquids and are therefore highly suitable for the absorption of exudates.
- Said natural sponge can in thin slices, the z. B. generated by thermal cutting, be placed on the wound.
- the flexible foam may optionally be configured in multiple layers, wherein the individual layers may preferably have thicknesses between 0.5 mm and 10 mm.
- the flexible foam may be open-celled and closed-celled.
- the material has punches and / or perforations, which accelerate the liquid inlet and passage in or through the flexible foam.
- the flexible foam can also be designed as integral foam.
- Alginates are extracted from brown algae and woven into a fibrous web. Chemically, they are polysaccharides, calcium and / or sodium salts of alginic acids. Alginates can absorb up to 20 times their own weight of liquid, while the wound exudate is stored in the cavities. The Ca 2+ ions contained in the alginate lattice are exchanged for the Na + ions from the exudate until the degree of saturation of Na ions in the alginate is reached. This leads to a swelling of the wound dressing and the conversion of the alginate fiber into a gel body by swelling of the fibers. Carboxymethylcellulose is present in particular in the form of sodium carboxymethylcellulose and is commercially available under the name "hydrofibre".
- the fibers are converted into a planar matrix.
- the fibers are gradually transformed into a gel pad that holds the fluid and does not release it again.
- the fibers are constructed so that the wound exudate is absorbed only in the vertical direction. This means that, as long as the capacity is sufficient, the exudate does not flow over the edge of the wound. In this way, wound edge maceration can be effectively prevented.
- All of the materials or sections mentioned above under points a-d may be sandwiched on or under said wound exudate absorbing body comprising a proportion of pulp.
- the former are integrated in the form of an insert in said wound exudate absorbing body, e.g. in the form of a strip, a round section or a cross-shaped section.
- the wound exudate absorbing body forms a correspondingly shaped window or at least a one-sided recess.
- one of the sections mentioned under points a-d forms a window or at least a one-sided recess in which the wound body absorbs absorbent bodies comprising a proportion of pulp.
- At least one liquid-impermeable laundry protection film section is arranged between the casing and the wound exudate absorbing body. This can preferably be arranged so that it covers only the central region of the wound care article.
- kits for acute, emergency or military medical or chronic care comprising a wound care article according to one of the preceding claims.
- such a kit is provided for wound compression and / or for the assessment of surgically applied hose exhausts
- the invention further provides for the use of a wound care article as a wound compress, for the padding of a wound, for the transfer of surgically applied Hose evacuation, destruction of Biof ⁇ lms and / or protection of the edge skin against maceration.
- a method for treating wounds comprising the use of a kit or a wound care article.
- a possibly provided sheath consists at least partially of a hydrophobic material, for example polypropylene, polyethylene or a hydrophobically finished natural material, such as cotton.
- a hydrophobic material for example polypropylene, polyethylene or a hydrophobically finished natural material, such as cotton.
- the hydrophobic properties of the sheath prevent it from sticking to the wound surface and help the wound exudate to reach the inside of the sheath more quickly.
- the sheath consists of a perforated sheet material, such as polypropylene or polyethylene, and is additionally provided with a layer consisting of Sheeting material such as polypropylene or polyethylene lined.
- the film material used for backing is laminated under the perforated film material, wherein the underlaid film material preferably has a thickness of l, 5g / qm, more preferably 2g / qm and particularly preferably 3g / qm.
- the casing may also be made of another plastic, in particular a polyurethane or polyethylene film or of artificial spider silk film.
- the material of the sheath may be structured such that the sheath has a rough inner surface and a smooth outer surface.
- the rough inner surface of the shell is formed by funnel-shaped perforations, each tapering towards the inner surface and terminating in a free opening edge ("protrusion"), this rough inner surface counteracting the displacements of the contents of the shell, so as to provide adhesion with adhesive dots
- the smooth outer surface of the sheath material may be formed by curved portions of material extending between the perforations, such sheath material may be referred to as "three-dimensional" as opposed to a bilaterally planar one, and is made of, for example: from the DE102006017194 the applicant of the present application, the disclosure content of which is fully referenced here.
- the casing of a wound dressing according to the invention has, at least in sections, an adhesive coating, preferably on the side facing away from the wound, with the aid of which it can be used, for example. with a bandage - can be fixed in the wound area.
- the sheath has a region projecting beyond the actual wound, which region is provided with adhesive strips for fixing.
- a flat material section can also be provided on the side of the wound dressing which faces away from the wound, and has at least in its edge regions an adhesive coating facing the skin, eg in the form of adhesive strips or surfaces (so-called "Iceland Dressing").
- Said areal section of material may in particular have semi-occlusive or semipermeable properties, ie it may be permeable to moisture, for example, but not to bacteria.
- the permeability for water vapor is preferably in the range between> 500 g to ⁇ 16000 g In 2 Ii- 1 (24 h).
- Adhesive materials for the above purposes are preferably physiologically acceptable adhesive agents such as e.g. Hydrocolloid or medically acceptable adhesives, such as solvent-free, biocompatible silicone adhesive or Po lycrylatkleb he be, which have good B emovmaschine against all current sterilization methods.
- physiologically acceptable adhesive agents such as e.g. Hydrocolloid or medically acceptable adhesives, such as solvent-free, biocompatible silicone adhesive or Po lycrylatkleb he be, which have good B e One sterilization methods.
- the absorbent body within the sleeve is asymmetrical, i. mostly arranged on one side.
- Such a wound care article can preferably be used in wound bags in which limited space prevails.
- the section of the wound dressing in which the absorbent body is located remains outside the wound bag. Due to the capillary forces exudates that are in such a wound bag, effectively absorbed and promoted wound healing here.
- the wound dressing has a lateral incision or a wedge-shaped recess, such that the edges of the incision or the recess can be arranged in an overlapping manner.
- the wound dressing has a wound-filling section.
- This can for example be designed so that it swells on contact with exudate and fills the wound up to the wound floor.
- the wound dressing is three-dimensionally shapeable, so that a concave shape results, for example, to adapt it to rest on a joint, a limb or a curved body part.
- the overlapping arranged edges of the incision or the recess can be fixed eg by Velcro, printheads, adhesive strips or other suitable fixing means.
- the wound dressing is shaped in three dimensions, such that it is adapted to rest on a joint, a limb or a curved body part.
- the wound dressing may be e.g. have a concave shape to make it e.g. adapted to rest on the heel of a foot or on a patient's elbow.
- the absorbent body which is arranged in the interior of the wound dressing, can be made removable. This embodiment is particularly advantageous if the absorbent body has been moistened beforehand or moistened by exudate exuding, since a gel forms here on account of the present superabsorbent polymers, which acts as a cushion and thus allows painless storage of said body part.
- the wound dressing adapts even better to the anatomical conditions due to moistening.
- the wound dressing is present at least partially in a rolled form.
- the originally flat wound dressing is rolled and possibly in its rolled form, e.g. is fixed by sewing, gluing or welding.
- Such a wound dressing is particularly suitable for use as a tamponade in wound bags; in particular, it has a wicking function for the exudates to be recorded.
- the wound dressing also has at least one nutritive active ingredient and / or active ingredient complex which acts as an inhibitor and has at least one disinfecting or decontaminating and / or at least one protease inhibiting action.
- the disinfectant active ingredient and / or active substance complex may be, for example, a composition of at least one vitamin or vitamin derivative, a metal ion and a detergent. It can also be an BLIS (bacteriocin like inhibitory substance), to act an antimicrobial peptide, an antibiotic, a silver preparation or coated magnetic particles. Particular preference is given here to mention quaternary ammonium compounds.
- the nutritive active ingredient and / or active ingredient complex may be a composition containing at least the components of an enteral and / or parenteral dietetics. It may also be at least one active element selected from the group containing insulin, recombinant insulin, proinsulin, an insulin-like growth factor (IGF), an insulin mimetic and / or a diabetic-specific, non-glucose or sucrose-based energy carrier ,
- the nutritive active and / or active complex may be a glycolysis enzyme, e.g. a hexokinase, which converts glucose to glucose-6-phosphate, thus reducing the level of glucose often elevated in diabetics by inducing glycolysis.
- a glycolysis enzyme e.g. a hexokinase, which converts glucose to glucose-6-phosphate, thus reducing the level of glucose often elevated in diabetics by inducing glycolysis.
- the protease-inhibiting active substance and / or active substance complex may be at least one active element selected from the group comprising protease inhibitors, superabsorbent polymers, antibodies against matrix -metallo-proteases (MMP, in particular against MMP 2, 7 and 9), chelators for divalent ones Cations (especially for Ca 2+ ), collagen, coated magnetic particles, acids, buffers, non-pathogenic acid-producing microorganisms, probiotics and / or symbiotics act.
- MMP matrix -metallo-proteases
- chelators for divalent ones Cations especially for Ca 2+
- collagen coated magnetic particles
- acids acids, buffers, non-pathogenic acid-producing microorganisms
- probiotics and / or symbiotics act.
- a carrier substance is provided in the wound dressing, which binds divalent cations (in particular Ca 2+ ).
- DE 102007030931 Further relationships and background to the nutritive, a disinfecting or decontaminating and / or proteases inhibiting agents and / or active substance complexes are described in the DE 102007030931 the applicant of the present application, the contents of which reference is made here in their entirety.
- DE102007030931 also describes other nutritive, disinfecting or decontaminating and / or protease-inhibiting active substances and / or active substance complexes which are likewise to be regarded as disclosed in this application.
- the wound dressing may contain a preparation containing phages and / or constituents thereof. Such a wound dressing is described in the DE 102007054127 of the applicant of the present invention, the contents of which are incorporated herein by reference.
- the wound dressing contains necrolytic and / or fibrinolytic enzymes. It may also contain angiogenesis- or epidermogenesis-promoting growth factors (in particular from the group of VEGF and EGF). Likewise, the wound dressing may contain attractants for macrophages, which phagocytize the phages released during phage therapy and bacterial residues (in particular endotoxins).
- At least one section of the sheath wall of the wound dressing has a reservoir for at least one nutritive, disinfecting or decontaminating, protease inhibiting, hemostatic and / or wound healing promoting active substance and / or active substance complex.
- Said reservoir may e.g. consist of an incorporated in the shell wall bag.
- the reservoir can consist of a section of the shell wall impregnated with said active substance and / or active substance complex, or the active substance is pressed into said section.
- the wound dressing may be added to substances that can increase the osmotic pressure.
- the substances include z. B. Osmodiuretics, such as mannitol.
- Mineral ion exchangers such as zeolites, bentonites or montmarylinites, may also be part of the wound dressing, in particular its mat.
- Zeolites can u. a. Absorb pollutants, such as heavy metals. Moreover, they develop a hemostatic effect.
- the article may also contain activated carbon. This is preferably dispersed in a thin layer, for example in a nonwoven layer, disposed on the side facing the wound, and in particular serves to absorb unpleasant odors from the wound area.
- the wound dressing may contain a preparation containing phages and / or constituents thereof. Such a wound dressing is described in the DE 102007054127 of the applicant of the present invention, the contents of which are incorporated herein by reference.
- the wound dressing according to the invention can also be introduced into a wound care system for wound drainage using negative pressure.
- a wound care system for wound drainage using negative pressure e.g. in the publications DE202004017052, WO2006048246 and DE202004018245 of the applicant of the present invention, the disclosure content of the present invention should be considered as belonging.
- an under-pressure wound-treating apparatus comprising a gas-tight wound-covering member constituting, in the state applied to the patient's body, a space remaining between the respective wound and the wound-covering member, and at least one terminal in contact with the space and by means of which the air in the room can be evacuated, the wound covering element being underlaid by at least one planar wound dressing receiving the wound exudate, whose volume increases in the course of the absorption process, so that the absorbed wound exudates within the wound dressing and thus below the wound covering element Removal of the wound dressing from the body of the patient remain, the wound dressing is at least one layer of superabsorbent enriched textile section, which is surrounded by a liquid-permeable shell, and the situation in plan view of her e Flat side has an area that is 3% to 90% smaller than that of the shell, so that the wound dressing can approach a circular shape in the vicinity of its entire filling capacity in cross-section.
- a multi-component dressing for wound treatment of the human or animal body using vacuum known comprising: a wound covering element for attachment to the skin and mucosal surface, at least one connection point, which is in contact with the wound space and evacuated via which the substances located in the wound space which has superabsorbent polymers, wherein the absorbed wound exudates remain bound to polymers in the wound space until they leave the wound space, the polymers being replaced by their own Binding capacity supports mutual synergies with the subatmospheric pressures.
- a drainage device for wound treatment using negative pressure comprising a gas-tight, sheet-like material wound covering element which is adhesively attached to the skin surface around the wound area in the body applied to the patient and one between the respective wound and the wound covering element remaining, sealed space forms, at least one drainage tube, which can be used in the space over which the substances in the room can be evacuated, and at least one disposed within the room, the wound exudates absorbing wound dressing, the at least one layer of enriched with superabsorbent textile section which is surrounded by a liquid-permeable sheath, wherein the absorbed wound exudates within the wound dressing and thus below the wound-covering element until removal of the wound dressing from the body of the patient verb body and w w ith the wound covering element has a gastight sealable treatment opening through which the wound dressing can be inserted into the room and removed from the room.
- the microfibers - or a microfiber-containing knitted fabric, spacer knits, knitted or nonwoven fabric - is provided as a padding, which underpins the shell body of the device and thus ensures permanent padding and permeability to liquids.
- the dimensionally stable, non-swelling properties of the microfibers are advantageous here, which have sufficiently high restoring forces even when a negative pressure of conventionally 80-250 mm Hg is applied.
- the microfibers used according to the invention represent an outstanding substitute for the foams otherwise used here, which are particularly lacking in the said restoring forces.
- a corresponding inventive embodiment is e.g. shown in Fig. 10.
- the wound dressing according to the invention may moreover have a form adapted to anatomical conditions.
- it may be formed, for example, in the form of a sleeve; which can be slipped over the one arm or a leg or a joint, or in the form of a dressing adapted to the heel, the elbow joint or the like.
- the wound dressing according to the invention can be designed in a particularly preferred manner so that it is suitable for levy around a surgically applied line.
- the wound dressing can e.g. have at least one slot that allows the wound dressing to be transferred around the body of a patient around a conduit (e.g., a drainage conduit or a catheter).
- a conduit e.g., a drainage conduit or a catheter.
- a web, a button, a Kettelnaht, a weld, a perforated bridge or other releasable connection may be provided, which allows the wound dressing in the usual manner or in the
- the wound dressing according to the invention does not swell on liquid absorption (lateral distribution) and locally increases in volume, so that this effect prevents the surrounding conduit from being narrowed or blocked the lateral distribution of the liquid a local volume increase in the wound care article (wound dressing) is prevented
- the wound dressing according to the invention can also be used excellently for the treatment of sutures (covering) and fistulas (insert).
- the wound dressing has at least one agent which can restrict the bleeding or the bleeding tendency.
- Said agent may be at least one chemically and / or physiologically acting active substance or active substance complex or at least one physically acting active element.
- a wound dressing is e.g. from the DE 102007030931 the applicant of the present application.
- the wound dressing for example, the wound dressing, for example
- substantially flat material section comprising absorption material which is formed from an absorbent fleece with superabsorbent polymers distributed therein and at least one chemically and / or physiologically active agent or complex of active substances, • as or in combination with a compression or compression bandage, especially as part of a compression therapy for venous leg ulcers
- a primary, non-insubstantially or only insubstantially absorbing wound dressing which has at least one chemically and / or physiologically acting active agent or active substance complex
- a secondary wound dressing arranged peripherally of this primary wound dressing, which contains superabsorbent polymers, optionally between both a diffusion barrier is arranged
- a bandage packet comprising a primary wound dressing with at least one chemically and / or physiologically acting active substance or complex of active substances and a winding section arranged on the wound dressing, which has superabsorbent polymers at least in sections, and / or
- the material section having a longitudinal extent comprising absorbent material, the material section having elastically deformable properties, and wherein the material section has superabsorbent polymers and optionally at least one chemically and / or physiologically acting active substance or active substance complex
- the chemically and / or physiologically acting active ingredient or active substance complex is preferably at least one substance or a composition which has haemostatic properties. These substances are known by the generic term "hemostats”.
- the chemically and / or physiologically acting active ingredient or active substance complex is preferably at least one substance or a composition which has haemostatic properties. These substances are known by the generic term "hemostats”.
- the physically acting active element is e.g. a binding, a pressure pad, a compression bandage or a compression bandage.
- wound care article in addition to classical primary and secondary dressings, also includes wound care wipes, swabs, tampons, wound tamponades and the like, which may have absorbent and non-absorbent properties.
- exudate refers to a wound fluid derived from the blood plasma via the inflammatory processes of wound edema. Just as the blood is responsible for the transport of nutrients and other messengers, and thus for the supply of various parts of the body, the exudate serves in a similar way the supply of the wound bed and the healing processes occurring therein. To cope with this multitude of functions, it contains a wide range of components, resulting in a specific weight that is slightly above that of water.
- exudate coordinates the various processes of wound healing both temporally and spatially through its high content of growth factors and cytokines. These are mainly formed by platelets, keratinocytes, macrophages and fibroblasts. They influence the motility, migration and proliferation of the various cells involved in wound healing. Thus, the infiltration of cells into the wound base is promoted as well as the supply of the newly formed granulation tissue by angiogenesis.
- the wound cleansing is also supported by the exudate. It contains various serine, cysteine and aspartate proteases as well as matrix metalloproteases, which in their activity severely regulate irreversibly damaged tissue and thus prepare the wound bed for the subsequent phases of healing.
- Components of the physiological exudate are in particular salts, glucose, cytokines and growth factors, plasma proteins, proteases (in particular matrix metalloproteases), granulocytes and macrophages.
- active substance complex is to be understood below as meaning those active substances or active ingredient complexes which are capable of limiting the bleeding or tendency to bleed, without having to use physical forces chemical and / or physiological interaction with the wound environment.
- active ingredient complex is to be understood below not only a complex in the chemical sense, but in particular a composition synergistically an effect-inducing agents.
- the term "physically acting active element” is to be understood in the following to mean an active element which is physically, i. by the exertion of pressure, tension, cold, and the like, to restrict the bleeding or bleeding tendency.
- ligation is to be understood in the following as an emergency medical measure that is capable of controlling the arterial blood flow, e.g. in one limb, to prevent unacceptable blood loss in a wound. Indications for such a ligation are usually traumatic effects that lead to injuries of at least one artery.
- chronic wounds should be understood to mean wounds that are not primarily due to traumatic effects. Although traumatic effects may have been the original cause of such a wound, the chronic wound is characterized mainly by delayed wound healing. Chronic wounds often show only slight bleeding, if at all, and often a strong exudation.
- tissue hemorrhage is to be understood as a bleeding that is not of arterial origin, but possibly of venous origin or of interstitial or capillary origin, and which in any case is so mild that it is not directly or indirectly life-threatening.
- acute bleeding wounds should be understood to mean those wounds that lead to large blood losses. As a rule, arterial haemorrhages are responsible for this, e.g. caused by traumatic effects. Acute bleeding wounds may u.U. be directly or life threatening. For this reason bleeding is a very high priority in acute bleeding wounds.
- compression bandage is to be understood in the following the known from emergency medicine pressure bandage, This consists of a not too hard, non-absorbent article (pressure pad) without sharp or hard edges, which is applied to an already covered wound and using a wrap is fastened with a moderate draft. By The pressure exerted reduces the circulation of the affected body part and the traumatically opened blood vessels are closed again.
- non-absorbent or only slightly absorbent wound dressing is intended to mean a wound dressing which has a low absorption capacity for liquids. Overall, the absorption capacity should be less than 60% by weight, preferably less than 20% by weight, of the dry weight of the wound dressing. The primary task of such a wound dressing is therefore not the uptake of blood or exudates, but the delivery of haemostatic agents in the context of the present invention.
- compression bandage is generally understood to mean a bandage which acts in a similar way to a compression bandage, but dispenses with said pressure pad.
- the pressure or the compression on the wound is exerted exclusively by the winding.
- the wrapping material can be elastic.
- mercerisation is understood to mean a cotton finishing process developed by the Englishman John Mercer in the mid-19th century. When Mercerizing cotton is exposed under the action of tensile concentrated sodium hydroxide solution. In this case, the fibers swell, the cross section changes from kidney-shaped to round and the length of the fibers is reduced by up to 25%. These structural changes lead to silk-like, wash-resistant gloss, better dyeability, higher strength, better dimensional stability and to the properties according to the invention.
- the achievable properties are determined by the mercerization process used (hot or cold merger, dry-in-wet or wet-in-wet, roll or vacuum impregnation) and the parameters of product tension, residence times and the caustic soda concentration.
- modified natural fibers refers in particular to the fibers known under the terms “mercerized fibers” and “curled fibers” which may be straight, wavy or curled and present as staple fibers or combed fibers
- a mixture of non-crimped fibers whose staple length is the staple length of the staple fibers fibers with a staple length between 10 mm and 130 mm are considered to be particularly advantageous.
- the fibers are advantageously suitable in the form of a fiber-air mixture, with or without the addition of adhesives or adhesives Lubricants are added in mist form to the fiber-air mixture in order to be sprayed onto a corresponding wound care article or parts of the wound care article.
- modified natural fibers chemical cellulose or cellulose fibers, which are obtained via the sulfite process, namely the acidic reaction of cellulose with sulfites and bisulfites, as special advantages of modified natural fibers over natural fibers is to mention the low hemicellulose and resin content , whereby a high white content of cellulose is achieved.
- fusible fibers which are bonded to the wound care article or parts thereof by thermal processes are suitable for bonding the fibers to the wound care article.
- water holding capacity liquid holding capacity
- dewatering capacity dewatering capacity
- an average dry fiber twist count of at least 4.5 twist nodes per millimeter b) an average wet fiber twist count of at least 3.0 twist nodes per millimeter and an average wet fiber twist count of at least 0.5 twist nodes less than the dry fiber Rotation number, c) a mean isopropyl alcohol retention value of less than 30% and d) an average water retention value of 28% to 50%.
- the mercerized fiber described in Table 1 on its physical properties is particularly suitable for use in a wound care article as it retains its drainability even after several PFI mill cycles, that is, with ever decreasing and mechanically stressed fiber.
- a modified hardwood natural fiber obtained by a sulfate process and usable in the wound care article of the present invention is shown in Table 2.
- a modified natural fiber of softwood retaining its mass and porosity and usable in the wound care article according to the invention is shown in Table 3.
- Ia and Ib wound care article in a sectional view consisting of layers of mercerized fiber, cellulose and superabsorbent polymers;
- Fig. 2 is a wound care article designed as a frame in a schematic representation
- FIG. 3 shows a wound care article designed as a slit compress in a schematic representation.
- FIG. 1a shows a wound care article consisting of two layers 1 and 2 which are surrounded by a common sleeve 3.
- the first layer 1 which preferably represents the wound-facing layer, consists of modified natural fiber 1.1, here of mercerized fiber.
- a second layer 2 is arranged, which consists of cellulose 2. 1, which is dispersed and immobilized therein Superabsorbent polymers 2.2 interspersed.
- the layer 2 may be, for example, an airlaid known by the applicant.
- liquid 4 impinging on the wound care article is laterally distributed over the first layer and then immediately directed vertically into the interior of the layer 2, with the effect that the cover 3 and the layer 1 are characterized by the liquid-absorbing behavior (FIG. Cellulose 2.1) and the absorption of the liquid (superabsorbent polymers 2.2) of layer 2 are back-dried.
- FIG. 1 b shows the same effect as described above for FIG. 1 a, but this is reinforced, ie, both the lateral distribution of the impinging liquid 4 and the re-drying of the casing 3 and the layer 1 which bears against the casing reinforced by the double layering of layers 1 and 2.
- the absorption capacity of liquids is increased.
- FIG. 2 shows a wound care article 300 with a recess 7 and a rim 8, so that a frame 5 is formed.
- the wound care article 100 consists of chemically and / or physically modified fibers, the layers which are applied to the fibers are dried or kept dry.
- the frame 5 can be placed under the wound dressing in combination with wound dressings to prevent wound edge maceration.
- the fibers should be solidified with each other so that they form a knitted fabric or woven or nonwoven, which is stamped or cut.
- FIG. 3 shows, by way of example, a wound care article 400 having a slot 9 for the transfer of surgically applied hose exhausts.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008045833 | 2008-09-05 | ||
PCT/EP2009/061571 WO2010026251A1 (de) | 2008-09-05 | 2009-09-07 | Wundpflegeartikel, aufweisend einen anteil an modifizierten naturfasern oder an kunstfasern |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2320844A1 true EP2320844A1 (de) | 2011-05-18 |
Family
ID=41347856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09782710A Withdrawn EP2320844A1 (de) | 2008-09-05 | 2009-09-07 | Wundpflegeartikel, aufweisend einen anteil an modifizierten naturfasern oder an kunstfasern |
Country Status (3)
Country | Link |
---|---|
US (2) | US20110213286A1 (de) |
EP (1) | EP2320844A1 (de) |
WO (1) | WO2010026251A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10058642B2 (en) | 2004-04-05 | 2018-08-28 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
CN101257875A (zh) | 2005-09-06 | 2008-09-03 | 泰科保健集团有限合伙公司 | 具有微型泵的独立伤口敷料 |
DE102006047041A1 (de) * | 2006-10-02 | 2008-04-10 | Birgit Riesinger | Flächenhafter Absorptionskörper |
HUE043133T2 (hu) | 2007-11-21 | 2019-07-29 | Smith & Nephew | Sebkötözés |
US8808274B2 (en) | 2007-11-21 | 2014-08-19 | Smith & Nephew Plc | Wound dressing |
GB0722820D0 (en) | 2007-11-21 | 2008-01-02 | Smith & Nephew | Vacuum assisted wound dressing |
US9061095B2 (en) | 2010-04-27 | 2015-06-23 | Smith & Nephew Plc | Wound dressing and method of use |
DE102010038006A1 (de) * | 2010-10-06 | 2012-04-12 | Birgit Riesinger | Verfahren zur Erhöhung der Haut- oder Wundkompatibilität eines Zellstoffvlieses |
US20120215194A1 (en) * | 2011-02-17 | 2012-08-23 | Marquette Candise K | Sanitary pad with increased absorbability |
RU2615075C2 (ru) | 2011-07-14 | 2017-04-03 | СМИТ ЭНД НЕФЬЮ ПиЭлСи | Перевязочный материал для ран и способы |
CA2853755A1 (en) * | 2011-11-01 | 2013-05-10 | Brightwake Limited | Wound dressings, and yarn useful therein |
DE102012100842A1 (de) * | 2012-02-01 | 2013-08-14 | Birgit Riesinger | Wundpflegeartikel, aufweisend mindestens eine Oberfläche mit abrasiven Eigenschaften |
WO2013113906A1 (de) | 2012-02-01 | 2013-08-08 | Birgit Riesinger | Wundpflegeartikel, aufweisend mindestens eine oberfläche mit abrasiven eigenschaften |
GB201207852D0 (en) * | 2012-05-04 | 2012-06-20 | Adv Med Solutions Ltd | Wound dressing |
AU2013264934B2 (en) | 2012-05-23 | 2017-07-20 | Smith & Nephew Plc | Apparatuses and methods for negative pressure wound therapy |
RU2015106111A (ru) | 2012-08-01 | 2016-09-27 | СМИТ ЭНД НЕФЬЮ ПиЭлСи | Раневая повязка и способ лечения |
EP2879636B1 (de) | 2012-08-01 | 2017-03-22 | Smith & Nephew PLC | Wundauflage |
US10246763B2 (en) | 2012-08-24 | 2019-04-02 | The Regents Of The University Of California | Magnesium-zinc-strontium alloys for medical implants and devices |
DE102012022756B4 (de) * | 2012-11-22 | 2016-11-03 | Karl Werner Wilke | Flächenartige, antimikrobielle Patientenunterlage sowie deren Verwendung |
GB2512841B (en) | 2013-04-08 | 2020-07-15 | Brightwake Ltd | Absorbent wound dressings |
WO2015059702A1 (en) * | 2013-10-24 | 2015-04-30 | Ionmed Ltd. | Cold plasma treatment |
CA2952284C (en) | 2014-06-18 | 2023-03-28 | Smith & Nephew Plc | Wound dressing |
EP3446665B1 (de) | 2014-10-06 | 2021-12-15 | 3M Innovative Properties Company | Absorbierende ionenaustauschsysteme, vorrichtungen |
US11096830B2 (en) * | 2015-09-01 | 2021-08-24 | Kci Licensing, Inc. | Dressing with increased apposition force |
GB2555584B (en) | 2016-10-28 | 2020-05-27 | Smith & Nephew | Multi-layered wound dressing and method of manufacture |
US11058771B2 (en) * | 2017-02-10 | 2021-07-13 | Boston Scientific Scimed, Inc. | Vascular ulcer treatment |
WO2018226592A1 (en) | 2017-06-07 | 2018-12-13 | Kci Usa, Inc. | Wound dressing with odor absorption and increased moisture vapor transmission |
WO2020081610A1 (en) * | 2018-10-15 | 2020-04-23 | Majhi Pinaki R | Composite fabric of water retentive and antimicrobial materials for sustained skin hydration |
DE202019105895U1 (de) * | 2019-10-23 | 2019-11-25 | Jens Fritsch | Trocken- und/oder Reinigungstuch |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6063982A (en) | 1995-07-06 | 2000-05-16 | International Paper Company (From Thomas L. Wiesemann And John J. Shoemaker Jr.) | Personal hygiene articles for absorbing fluids |
US20030201051A1 (en) * | 1992-08-17 | 2003-10-30 | Weyerhaeuser Company | Particle binding to fibers field of the invention |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE609037C (de) * | 1934-02-25 | 1935-06-01 | Ernst Gelinsky Dr | Kompresse |
US2997166A (en) * | 1959-06-16 | 1961-08-22 | Pratt Mfg Corp | Packages for flat articles such as surgical supplies and method of wrapping such articles |
US4898642A (en) * | 1986-06-27 | 1990-02-06 | The Procter & Gamble Cellulose Company | Twisted, chemically stiffened cellulosic fibers and absorbent structures made therefrom |
US4909243A (en) * | 1988-07-20 | 1990-03-20 | E. R. Squibb & Sons, Inc. | Wound dressing system |
SE508961C2 (sv) * | 1992-11-17 | 1998-11-23 | Sca Hygiene Prod Ab | Absorberande struktur och absorberande alster innehållande strukturen ifråga |
US5703225A (en) * | 1995-12-13 | 1997-12-30 | Kimberly-Clark Worldwide, Inc. | Sulfonated cellulose having improved absorbent properties |
US20010036784A1 (en) * | 1996-05-31 | 2001-11-01 | Anette Buschka | Textile fibre reinforced absorbent material |
USH2062H1 (en) * | 1998-09-03 | 2003-04-01 | Kimberly-Clark Worldwide | Nursing pad |
US6376011B1 (en) * | 1999-04-16 | 2002-04-23 | Kimberly-Clark Worldwide, Inc. | Process for preparing superabsorbent-containing composites |
JP2004503328A (ja) * | 2000-07-18 | 2004-02-05 | コロプラスト アクティーゼルスカブ | 包帯剤 |
US6620293B2 (en) * | 2001-04-11 | 2003-09-16 | Rayonier Inc. | Crossed-linked pulp and method of making same |
US7576257B2 (en) * | 2006-06-06 | 2009-08-18 | Lagreca Sr Alfred J | Reclosable wound dressing system |
-
2009
- 2009-09-07 EP EP09782710A patent/EP2320844A1/de not_active Withdrawn
- 2009-09-07 WO PCT/EP2009/061571 patent/WO2010026251A1/de active Application Filing
-
2011
- 2011-03-07 US US13/042,441 patent/US20110213286A1/en not_active Abandoned
-
2012
- 2012-09-28 US US13/631,742 patent/US20130096524A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030201051A1 (en) * | 1992-08-17 | 2003-10-30 | Weyerhaeuser Company | Particle binding to fibers field of the invention |
US6063982A (en) | 1995-07-06 | 2000-05-16 | International Paper Company (From Thomas L. Wiesemann And John J. Shoemaker Jr.) | Personal hygiene articles for absorbing fluids |
Non-Patent Citations (1)
Title |
---|
See also references of WO2010026251A1 |
Also Published As
Publication number | Publication date |
---|---|
US20130096524A1 (en) | 2013-04-18 |
WO2010026251A1 (de) | 2010-03-11 |
US20110213286A1 (en) | 2011-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2320844A1 (de) | Wundpflegeartikel, aufweisend einen anteil an modifizierten naturfasern oder an kunstfasern | |
EP2593058B1 (de) | Wundpflegeartikel zur wundbehandlung unter einsatz von unterdruck enthaltend mikrofasern | |
EP2809363B1 (de) | Wundpflegeartikel, aufweisend mindestens eine oberfläche mit abrasiven eigenschaften | |
EP3033116B1 (de) | Wundpflegeartikel aufweisend superabsorbierende fasern und superabsorbierende partikel | |
WO2009019227A2 (de) | Wundpflegeartikel, aufweisend superabsorbierende polymere in faser- und/oder garnform | |
WO2009019229A2 (de) | Wundpflegeartikel, aufweisend mindestens eine lage aufweisend superabsorbierende polymere, sowie eine lage aufweisend einen weichschaumstoff | |
DE60209813T2 (de) | Hydrogelschicht enthaltender, absorbierender wundverband | |
EP2153807A1 (de) | Wundpflegeartikel, aufweisend Textilbänder mit Fasern mit gelbildenden Eigenschaften sowie Fasern mit nicht gelbildenden Eigenschaften | |
EP2185206B1 (de) | Blutstillender wundpflegeartikel | |
EP2481385B1 (de) | Wundpflegeartikel mit absorbierender Hülle | |
EP2787944A1 (de) | Set aus wundauflage und wundfüller | |
EP2747792A1 (de) | Hygiene- oder pflegeartikel aufweisend einen anteil an kupfer bzw. kupferionen | |
DE102012100842A1 (de) | Wundpflegeartikel, aufweisend mindestens eine Oberfläche mit abrasiven Eigenschaften | |
DE102009031992A1 (de) | Vorrichtung zur Unterdrucktherapie von Wunden | |
DE202012101743U1 (de) | Wundpflegeartikel | |
WO2012168298A1 (de) | Wundabdeckungsartikel mit vorbereitung zum anschluss einer unterdruckvorrichtung | |
DE102011001832A1 (de) | Wundpflegeartikel mit zielgerichtet verformbarer Hülle | |
DE102007049430A1 (de) | Wundpflegeartikel, aufweisend mindestens einen Anteil an stützenden Fasern und einen Anteil an hydroaktiven Polymeren | |
DE102007063294A1 (de) | Wundauflage enthaltend superabsorbierende Polymere | |
EP2747793A1 (de) | Absorbierender hygiene- oder pflegeartikel aufweisend einen bahnförmigen bestandteil mit einem anteil an mindestens einem elementaren oder in ionenform vorliegenden schwermetall | |
DE102007049428A1 (de) | Wundpflegeartikel, aufweisend mindestens eine Lage aufweisend superabsorbierende Polymere, sowie eine Lage aufweisend einen Weichschaumstoff | |
WO2009019226A2 (de) | Wundpflegeartikel mit unmittelbar anliegender kaschierung | |
DE102011050047A1 (de) | Wundpflegeartikel für Kavitäten | |
WO2016055483A1 (de) | Wundpflegeprodukt, aufweisend ein nanofaser-vlies | |
DE202012102259U1 (de) | Bezug für einen Hygiene- oder Pflegeartikel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110302 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
17Q | First examination report despatched |
Effective date: 20111027 |
|
DAX | Request for extension of the european patent (deleted) | ||
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: RIESINGER, BIRGIT |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: RIESINGER, BIRGIT |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160401 |